首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OSM |
| Uniprot No | P13725 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-221aa |
| 氨基酸序列 | AAIGSCSKEY RVLLGQLQKQ TDLMQDTSRL LDPYIRIQGL DVPKLREHCR ERPGAFPSEE TLRGLGRRGF LQTLNATLGC VLHRLADLEQ RLPKAQDLER SGLNIEDLEK LQMARPNILG LRNNIYCMAQ LLDNSDTAEP TKAGRGASQP PTPTPASDAF QRKLEGCRFL HGYHRFMHSV GRVFSKWGES PNRSRR |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OSM(Oncostatin M)重组蛋白的示例参考文献，涵盖不同研究方向。请注意，这些文献为模拟示例，实际文献需通过学术数据库检索获取：
---
1. **文献名称**：Expression and purification of recombinant human Oncostatin M in *Escherichia coli*
**作者**：Zhang Y, et al.
**摘要**：本研究开发了一种高效的大肠杆菌表达系统，通过密码子优化和亲和层析技术纯化出具有生物活性的重组人OSM蛋白，为大规模生产提供了可行方案。
2. **文献名称**：Oncostatin M regulates mesenchymal stem cell differentiation through the STAT3 pathway
**作者**：Li H, Wang J.
**摘要**：利用重组OSM处理间充质干细胞，证实其通过激活STAT3信号通路促进成骨分化，提示OSM在骨组织工程中的潜在应用价值。
3. **文献名称**：Recombinant Oncostatin M induces inflammatory responses in synovial fibroblasts: Implications for rheumatoid arthritis
**作者**：Tanaka S, et al.
**摘要**：研究发现重组OSM可刺激类风湿关节炎患者的滑膜纤维细胞分泌IL-6和MMPs，揭示了OSM在关节炎病理机制中的关键作用。
4. **文献名称**：Functional interaction between recombinant OSM and IL-6 in hepatic cell models
**作者**：Müller R, et al.
**摘要**：在肝细胞模型中，重组OSM与IL-6表现出协同效应，共同调控急性期蛋白表达，为肝脏炎症研究提供了新视角。
---
**建议检索关键词**：在PubMed、Google Scholar等平台搜索“recombinant Oncostatin M”、“OSM protein expression”、“OSM signaling”等，可获取更多最新研究。
**Background of Recombinant OSM (Oncostatin M)**
Oncostatin M (OSM), a member of the interleukin-6 (IL-6) cytokine family, is a pleiotropic glycoprotein initially identified for its ability to inhibit the proliferation of certain cancer cells. It is primarily produced by activated T lymphocytes, macrophages, dendritic cells, and neutrophils. OSM exerts its biological effects by binding to two distinct receptor complexes: the type II OSM receptor (OSMRβ/gp130) and, in humans, the leukemia inhibitory factor receptor (LIFR/gp130). This dual receptor interaction enables OSM to regulate diverse cellular processes, including inflammation, immune responses, cell growth, differentiation, and tissue remodeling.
The development of recombinant OSM involves cloning the OSM gene into expression vectors (e.g., bacterial, mammalian, or yeast systems) to produce purified, bioactive protein. Recombinant technology ensures high yield and consistency, overcoming limitations of native OSM isolation from natural sources. Mammalian expression systems are preferred for generating glycosylated OSM, which closely mimics the native structure and function.
OSM has garnered attention for its dual role in disease contexts. In cancer, it exhibits tumor-suppressive or pro-tumorigenic effects depending on the microenvironment. It also contributes to fibrotic diseases (e.g., liver and lung fibrosis) by promoting extracellular matrix deposition and activating fibroblasts. Conversely, OSM supports tissue repair and regeneration, influencing stem cell differentiation and wound healing.
Clinically, recombinant OSM is explored as a therapeutic target or agent. Inhibiting OSM signaling shows promise in treating inflammatory disorders like rheumatoid arthritis or fibrosis, while its regenerative properties are studied in organ repair strategies. However, challenges remain in understanding its context-dependent mechanisms and optimizing delivery approaches. Overall, recombinant OSM serves as a critical tool for unraveling its complex biology and translating findings into targeted therapies.
×
